Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of linagliptin 5 mg tablets versus Trajenta 5 mg tablets in healthy Thai volunteers under fasting
TCTR20220406003Phase 1Not yet recruiting
- Sponsor
- T. Man Pharma
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of linagliptin (2 arms), sponsored by T. Man Pharma. Primary endpoint: Bioequivalence to Trajenta 5 mg. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
linagliptin
Beyond the preview
Go deeper on TCTR20220406003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220406003.